<DOC>
	<DOCNO>NCT02771743</DOCNO>
	<brief_summary>The purpose study improve outcome high risk neuroblastoma tailor treatment intensity tandem high dose chemotherapy accord treatment response induction chemotherapy .</brief_summary>
	<brief_title>Response-based Treatment High-risk Neuroblastoma</brief_title>
	<detailed_description>Although outcome high-risk neuroblastoma improve introduction high-dose chemotherapy autologous stem cell transplantation ( HDCT/autoSCT ) , outcome still need unsatisfactory . In investigator 's previous study , good responder great reduction tumor volume induction chemotherapy show low relapse-free survival compare poor responders.Simultaneously , reduction tumor volume also great patient die treatment related mortality patient relapse tumor . These finding suggest tailor treatment intensity accord early tumor response induction chemotherapy may improve patient outcome . So , study investigator tailor treatment intensity high dose chemotherapy accord treatment response induction chemotherapy .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Patients newly diagnose high risk neuroblastoma Patients informed consent Patients progressive disease relapse Patients underwent high dose chemotherapy Patients organ dysfunction follow ( creatinine elevation &gt; 3 x upper limit normal , Total bilirubin &gt; 3 x upper limit normal , aspartate transaminase/alanine transaminase &gt; 5 x upper limit normal ) , ejection fraction &lt; 40 % Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>High risk</keyword>
	<keyword>Tandem high dose chemotherapy</keyword>
</DOC>